A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. - Cappellini,MD.; Cohen,A.; Piga,A.; Bejaoui,M.; Perrotta,S.; Agaoglu,L.; Aydinok,Y.; Kattamis,A.; Kilinc,Y.; Porter,J.; Capra,M.; Galanello,R.; et al. (Blood, 2006)